Affinity Asset Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Affinity Asset Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8M	Sell	30,000 -65,000	-68%	-$15.2M	0.36%	67
2026 Q1	$21.7M	Buy	95,000 +65,000	+217%	+$14.6M	1.12%	29
2025 Q4	$6.4M	Buy	+30,000	New	+$6.2M	0.36%	57
2024 Q1	–	Sell	-20,000	Closed	-$2.52M	–	101
2023 Q4	$2.52M	Sell	20,000 -26,400	-57%	-$2.63M	0.46%	53
2023 Q3	$4.34M	Sell	46,400 -11,360	-20%	-$1.06M	1.22%	28
2023 Q2	$5.16M	Buy	57,760 +17,760	+44%	+$1.55M	1.8%	19
2023 Q1	$4.29M	Sell	40,000 -30,997	-44%	-$3.55M	1.42%	24
2022 Q4	$8.67M	Sell	70,997 -29,003	-29%	-$3.37M	3.4%	5
2022 Q3	$10.3M	Sell	100,000 -25,087	-20%	-$2.38M	2.88%	8
2022 Q2	$11.6M	Buy	125,087 +5,087	+4%	+$479K	4.9%	5
2022 Q1	$14.1M	Buy	+120,000	New	+$13.9M	2.25%	5
2021 Q4	–	Sell	-35,910	Closed	-$5.72M	–	56
2021 Q3	$5.72M	Buy	35,910 +15,910	+80%	+$2.18M	1.45%	17
2021 Q2	$2.63M	Hold	20,000	–	–	0.94%	27
2021 Q1	$2.58M	Buy	20,000 +10,000	+100%	+$1.52M	0.88%	31
2020 Q4	$1.67M	Buy	+10,000	New	+$1.65M	0.88%	31

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Affinity Asset Advisors's ASND Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Ascendis Pharma A/S (ASND) stake by 68% in Q2 2026, selling an estimated $15.2M and leaving 30,000 shares worth $8M. The position accounts for 0.36% of the portfolio, ranked #67.

Affinity Asset Advisors first reported a position in ASND in Q4 2020 and has held it in 15 quarters since. The position peaked at $21.7M in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Affinity Asset Advisors held 30,000 shares of Ascendis Pharma A/S worth $8M as of Q2 2026.
Affinity Asset Advisors sold 65,000 Ascendis Pharma A/S shares in Q2 2026, an estimated $15.2M.
Ascendis Pharma A/S made up 0.36% of Affinity Asset Advisors's portfolio in Q2 2026, its #67 holding.
Affinity Asset Advisors first reported a position in Ascendis Pharma A/S in Q4 2020 and has held it in 15 quarters since.
Affinity Asset Advisors's Ascendis Pharma A/S position peaked at $21.7M in Q1 2026.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.